A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg Once Daily) in Elderly Subjects With Major Depressive Disorder

GlaxoSmithKline1 site in 1 country364 target enrollmentJune 2004

Overview

This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).

Registry

clinicaltrials.gov

Start Date

June 2004

End Date

October 2005

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Sponsor

•Primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current episode for at least 8 weeks.

•Patient has current or past history of seizure disorder or brain injury.
•Patient has a diagnosis of anorexia or bulimia within the past 12 months.
•Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s).
•Patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.

Montgomery-Asberg Depression Rating Scale

Montgomery-Asberg Depression Rating Scale Clinical Global Impression Improvement Scale Clinical Global Impression Severity Scale Hamilton Anxiety Rating Scale